Suggested remit: To appraise the clinical and cost effectiveness of xanomeline tartrate–trospium chloride within its marketing authorisation for treating schizophrenia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Criteria within the 2024 Voluntary Scheme for Pricing, Access and Growth (VPAG) met as a new active substance.
- Process:
- STA Standard
- ID number:
- 6716
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6716:
- 29 May 2026 - 26 June 2026
- Stakeholder workshop:
- 23 July 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 May 2026 | In progress. Scoping commencing |
| 15 December 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual